Image Sourced ShutterStock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical technology company Volpara raised $55 million in the first quarter of the 2020 financial year
  • Volpara acquired medical software company MRS Systems which is expected to generate US$4.5 in annual recurring revenue
  • Volpara’s share price is up just over six per cent today, currently sitting at $1.64 per share.

Medical technology company Volpara reports it raised $55 million during the first quarter of the 2020 financial year.

Volpara produces artificial intelligence imaging algorithms which help with in early breast cancer detection.

Alongside the capital raise, the company acquired medical software company MRS Systems out of Seattle, United States.

The company explained the acquisition sets its up with an “experienced US office, much greater market penetration and strong cross-selling opportunities”.

Volpara also highlights gaining MRS Systems “provides a range of products today and in the future that offer much greater potential average revenue per user for our sales team to sell into the US and other markets”.

MRS Systems’ software track and report results from breast and lung cancer screenings, among others. Patient history, risk factors and outcomes of X-Rays, MRIs and Ultrasounds can be logged, with options for patient and physician access.

Currently the company has NZ$39.9 million cash on hand and operating costs remain on track with no debt accumulated.

Annual Recurring Revenue (ARR) at the end of the first quarter was NZ$13.6M for breast sales and NZ$970,000 for lung sales. MRS Systems is expected to turn out US$4.5 million in ARR.

Volpara’s share price is up just over six per cent today, currently sitting at $1.64 per share.

VHT by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…